Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Samyang Biopharmaceuticals Corporation
The purpose of this study is to evaluate efficacy and safety of AC followed by Taxotere versus AC followed by Nanoxel M as neoadjuvant chemotherapy in breast caner patients.
Age
19–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
1. Patients who were diagnosed with primary breast cancer by core biopsy
2. Patients who have been identified as HER2 negative in the tissue obtained through core needle biopsy and have confirmed the positive / negative status of ER (Estrogen receptor) and Progesterone receptor (PR)
* HER2 positive is defined as IHC 3+ or FISH +
3. Patinets whose TNM stage confirmed by CT or MRI (T2-T3, anyN, M0 or T1-3, N1-3, M0)
You may not be if
1. Patients who have distant metastasis
2. Patients who have cystitis or urinary obstruction
3. Patients who have history of thromboembolism or coagulation disorder
4. Patients who have Interstitial lung disease ans liver cirrhosis ( \> Child-Pugh class B)
5. Patients who have Insulin-Dependent Type II diabete mellitus
Clareo Health | Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer
